- NeoVentures’ Neomer aptamer selection method replaces the traditional SELEX process, offering a closed and reproducible space for aptamer development, ensuring consistency in drug level detection.
- The inclusion of an in-silico immune tolerance step enhances Neomer aptamers’ specificity and selectivity, making them more precise in detecting drugs, especially in low concentrations.
- Neomer aptamers surpass antibodies in size, stability, and binding properties, providing a versatile and advanced solution for accurate drug level detection in molecular diagnostics.
In the realm of molecular diagnostics and targeted therapies, the accurate detection of drug levels, especially in low concentrations, is crucial for effective patient treatment. Traditional methods often rely on antibodies, but emerging technologies are challenging the status quo. NeoVentures, a pioneer in the field, is at the forefront of this revolution with their patented Neomer aptamer selection method. This innovative approach not only replaces the traditional SELEX method but also transforms aptamer selection from an art to a reproducible science.
The Neomer Advantage:
- Reproducibility: NeoVentures’ Neomer selection method marks a paradigm shift from the unpredictable nature of traditional aptamer selection processes. By moving the selection from an art to a science in a closed space, Neomer ensures a reproducibility that was once elusive in the field. This consistency is essential for reliable and standardized diagnostic assays.
- In-Silico Immune Tolerance: One of the key features that sets Neomer apart is its incorporation of an in-silico immune tolerance step. This step fine-tunes the aptamer selection process, ensuring that the resulting aptamers exhibit high specificity and selectivity for their target. This level of precision is unparalleled and enhances the overall performance of the aptamers in drug level detection.
- Specificity and Selectivity: Traditional aptamer selection methods may yield molecules with high affinity but lacking specificity, leading to cross-reactivity issues. Neomer’s in-silico immune tolerance step refines the aptamers, enhancing their specificity and selectivity. This precision is particularly advantageous in detecting drugs present in low concentrations, where accuracy is paramount.
- High Affinity: While focusing on specificity, Neomer does not compromise on affinity. The aptamers generated through this method retain their high affinity for the target, ensuring sensitivity in drug level detection. This dual benefit of high affinity and specificity positions Neomer aptamers as superior tools in molecular diagnostics.
- Versatility: Neomer aptamers offer versatility in applications, making them suitable for a wide range of drug detection scenarios. Whether monitoring therapeutic drug levels in patients or conducting research in a laboratory setting, the adaptability of Neomer aptamers contributes to their widespread applicability.
- Advancement Beyond Antibodies: Compared to antibodies, Neomer aptamers demonstrate several advantages. They are smaller in size, more stable, and can be synthesized with greater ease. Additionally, their ability to bind with high specificity and affinity to a diverse range of targets positions them as a cutting-edge alternative to traditional antibodies.
In the quest for accurate and reliable detection of drug levels, NeoVentures’ Neomer aptamers shine as a beacon of innovation. The transition from art to science in aptamer selection, coupled with the in-silico immune tolerance step, marks a significant leap forward. The reproducibility, specificity, and high affinity of Neomer aptamers, combined with their versatility, make them the ideal choice for applications where precision in drug level detection is paramount. As the landscape of molecular diagnostics evolves, Neomer aptamers from NeoVentures stand as a testament to the ongoing transformation of the field.
Dr. Gregory Penner academic training was a blend of very practical plant breeding theory combined with molecular biology. He has used this blend of biology and mathematics to first develop and lead a cereal biotechnology research team with the government of Canada and subsequently as a global research leader with Monsanto Inc. He has been a thought leader in aptamer development globally for the last twenty years as CEO and President of NeoVentures. He has led this company to financial stability without outside investment with an integrated approach to aptamer discovery and commercialization. In 2015, he co- founded a second company, NeoNeuro in Paris France, focused on an innovative approach to identify Aptamarkers for complex diseases.